340B Oversight Gathering Steam In Senate; HELP Committee Plans Hearing
Executive Summary
With several pieces of legislation in play that could overhaul 340B transparency and oversight, hospitals and sponsors will have a lot on the line during Senate hearing planned for 'early spring.'
You may also be interested in...
340B Provider Reforms Gaining Momentum In Congress
House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.
FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals
Health policy experts discuss ways Medicare coverage policy may evolve in the coming years and how efforts to smooth the transition between accelerated drug approvals and Medicare reimbursement decisions could play out.
Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts
Lack of detail on data elements that would be required through the portal has stakeholders wondering if the Centers for Medicare and Medicaid Services has really found a way to make the registry requirement less of a threat to access for Alzheimer’s drugs with traditional FDA approval.